(Q51562915)

7 April 2018

title

Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus? (English)

1 reference

7 April 2018

0 references

1 reference

1 reference

Scott R

1

1 reference

7 April 2018

Lintott CJ

2

1 reference

7 April 2018

Zimmet P

3

1 reference

7 April 2018

Campbell L

4

1 reference

7 April 2018

Bowen K

5

1 reference

7 April 2018

Welborn T

6

1 reference

7 April 2018

publication date

1 March 1999

1 reference

7 April 2018

Diabetes Research and Clinical Practice

published in

1 reference

7 April 2018

volume

43

1 reference

7 April 2018

issue

3

1 reference

7 April 2018

page(s)

179-185

1 reference

7 April 2018

Banting lecture 1988. Role of insulin resistance in human disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900009-1

7 January 2021

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900009-1

7 January 2021

The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900009-1

7 January 2021

Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900009-1

7 January 2021

International variations in mortality among diabetic patients: the WHO Multinational Study of Vascular Disease in Diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900009-1

7 January 2021

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900009-1

7 January 2021

Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900009-1

7 January 2021

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900009-1

7 January 2021

The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900009-1

7 January 2021

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900009-1

7 January 2021

Plasma proinsulin in recently diagnosed type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900009-1

7 January 2021

Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900009-1

7 January 2021

Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900009-1

7 January 2021

10.1016/S0168-8227(99)00009-1

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

10369427

1 reference

7 April 2018